Amphastar Pharmaceuticals, Inc. AMPH R2KR3KPHARMA
Company Overview
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Why Investors Should Care
Net profit has compounded at 15.1% per year over the last five years.
Revenue has grown at a 11.1% CAGR over the past five years.
Trades at a P/E of 14.9, below the sector median of 25.4.
Operating margin of 21.6% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $719.89M (-1.7% YoY); net profit $98.09M.
- Trailing 12 Months Year-on-year growth — revenue +5.4%, earnings +4.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.1%, profit CAGR 15.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.07% |
| 1 Year: | 5.40% |
Compounded Profit Growth
| 5 Years: | 15.13% |
| 1 Year: | 4.70% |
Stock Price Performance
| 1 Year: | -17.52% |
| 6 Months: | +17.42% |
| 3 Months: | +31.07% |
| 1 Month: | -4.30% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)47.47 · Neutral
P/E of 14.88 is below the sector median of 25.45 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.1% over 5 years.
- Profit CAGR of 15.1% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AMPH Amphastar Pharmaceuticals, Inc. R2KR3KPHARMA | 25.14 | 14.88 | $1.07B | 0.00% | 9.54% | 10.30% | 11.07% | 15.13% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 56.67M | 65.19M | 57.92M | 60.40M | 58.39M | 71.04M | 75.54M | 89.69M | 79.79M | 79.05M | 80.14M | 83.38M | 84.69M | 85.81M | 83.43M | 103.02M | 101.66M | 112.20M | 120.37M | 123.47M | 120.13M | 140.02M | 145.71M | 180.56M | 171.84M | 182.39M | 191.21M | - | 170.53M | 174.41M | 191.84M | 183.10M | 171.17M | 183.90M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 85.28M | 87.92M | 93.19M | 97.44M | 100.85M | - |
| Gross Profit | 17.58M | 33.17M | 24.90M | 31.71M | 27.61M | 19.96M | 22.81M | 26.66M | 20.55M | 20.49M | 16.97M | 26.06M | 29.26M | 34.69M | 30.90M | 32.39M | 35.25M | 33.38M | 36.82M | 33.18M | 36.51M | 44.95M | 47.38M | 51.18M | 55.83M | 63.36M | 58.51M | 73.84M | 72.74M | 108.40M | 90.10M | 95.17M | 101.94M | - | 85.25M | 86.49M | 98.65M | 85.67M | 70.32M | 93.47M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.96M | 44.31M | 73.33M | 50.06M | 56.69M | - |
| Operating Income | -3.75M | - | 4.08M | 10.33M | 5.80M | - | 1.40M | 2.19M | -2.94M | - | -9.78M | -2.94M | 2.55M | - | -3.17M | 973.00K | 2.40M | - | 7.48M | -2.92M | 3.52M | 10.31M | 10.56M | 24.77M | 21.61M | 24.82M | 23.23M | 33.43M | 36.90M | 72.68M | 48.01M | 55.22M | 57.05M | - | 37.29M | 42.18M | 25.32M | 35.61M | 13.63M | 39.73M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.35M | 61.85M | 43.56M | 54.53M | 33.10M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.29M | 6.28M | 6.28M | 6.63M | 6.55M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.86M | 39.34M | 21.51M | 31.91M | 10.05M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.58M | 8.30M | 4.16M | 7.49M | 3.63M | - |
| Net Income | -3.01M | 7.53M | 2.49M | 6.89M | 3.89M | -2.74M | 893.00K | 1.97M | 99.00K | 1.47M | -7.14M | -2.85M | 2.39M | 1.87M | 868.00K | 47.79M | 1.31M | -1.03M | 3.95M | -192.00K | 3.92M | 5.04M | 7.77M | 29.55M | 24.25M | 17.35M | 15.87M | 26.03M | 26.12M | 49.22M | 43.18M | 37.95M | 40.43M | - | 25.29M | 31.03M | 17.35M | 24.43M | 6.42M | 30.35M |
| Diluted EPS | -0.07 | 0.16 | 0.05 | 0.15 | 0.08 | -0.06 | 0.02 | 0.04 | 0.00 | 0.02 | -0.15 | -0.06 | 0.05 | 0.04 | 0.02 | 0.96 | 0.03 | -0.02 | 0.08 | 0.00 | 0.08 | 0.10 | 0.16 | 0.59 | 0.47 | 0.33 | 0.30 | 0.50 | 0.49 | 0.91 | 0.81 | 0.73 | 0.78 | - | 0.51 | 0.64 | 0.37 | 0.51 | 0.14 | 0.67 |
| R&D Expense | 11.12M | - | 8.61M | 10.59M | 9.72M | - | 11.25M | 10.73M | 10.07M | - | 14.03M | 15.46M | 11.34M | - | 14.61M | 16.00M | 18.61M | - | 15.30M | 16.15M | 17.64M | 14.77M | 18.12M | 10.76M | 16.22M | 22.80M | 18.51M | 19.82M | 16.84M | 16.66M | 17.04M | 17.65M | 21.08M | - | 20.10M | 20.08M | 22.35M | - | 26.74M | 22.16M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 204.32M | 229.68M | 210.46M | 251.52M | 255.16M | 240.18M | 294.67M | 322.36M | 349.85M | - | 498.99M | 644.39M | 731.97M | 719.89M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 250.13M | 293.27M | 358.11M | 363.83M |
| Gross Profit | 90.30M | 86.96M | 51.26M | 77.35M | 104.20M | 90.51M | 106.98M | 131.92M | 143.34M | - | 248.86M | 351.12M | 373.86M | 356.06M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 141.36M | 154.13M | 168.44M | 215.65M |
| Operating Income | 25.40M | 17.49M | -17.98M | -6.90M | 15.38M | -1.27M | -8.62M | -39.00K | 10.95M | - | 107.50M | 196.99M | 205.42M | 140.40M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | 146.16M | 240.29M | 277.31M | 212.31M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 1.85M | 27.16M | 30.34M | 25.48M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | 116.04M | 171.36M | 189.76M | 123.62M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 23.48M | 31.83M | 29.67M | 25.53M |
| Net Income | 18.09M | 11.86M | -10.70M | -2.79M | 9.82M | 3.65M | -5.74M | 48.94M | 1.40M | - | 91.39M | 137.54M | 159.52M | 98.09M |
| Diluted EPS | 0.46 | 0.31 | -0.25 | -0.06 | 0.21 | 0.08 | -0.12 | 0.98 | 0.03 | - | 1.74 | 2.60 | 3.06 | 2.03 |
| R&D Expense | 31.16M | 33.02M | 28.87M | 37.27M | 41.52M | 43.50M | 57.56M | 68.85M | 67.23M | 60.93M | 74.77M | 73.74M | 73.91M | 85.84M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 338.75M | 389.37M | 390.14M | 427.74M | 451.07M | 513.56M | 586.97M | 631.24M | - | 741.99M | 1.51B | 1.58B | 1.63B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 378.32M | 489.60M | 534.07M | 636.02M |
| Cash & Equivalents | 53.74M | 50.21M | 53.59M | 67.83M | 66.07M | 72.35M | 65.59M | 86.34M | 73.69M | 92.64M | - | 156.10M | 144.30M | 151.61M | 170.18M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | 103.58M | 105.83M | 153.74M | 176.89M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 88.80M | 114.94M | 136.29M | 143.56M |
| Total Liabilities | - | - | 87.20M | 107.51M | 94.63M | 98.48M | 117.34M | 149.20M | 159.44M | 182.51M | - | 213.33M | 873.49M | 845.17M | 840.49M |
| Current Liabilities | - | - | 65.40M | 62.59M | 59.95M | 60.62M | 67.19M | 106.83M | 90.01M | 112.20M | - | 94.86M | 225.41M | 173.76M | 158.16M |
| Long Term Debt | - | - | - | 42.68M | 40.30M | 36.03M | 45.72M | 49.10M | 46.32M | 45.92M | - | 72.84M | 589.58M | 601.63M | 608.75M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 102.58M | 623.64M | 650.55M | 656.00M |
| Total Equity | 208.52M | 233.44M | 251.54M | 281.86M | 295.51M | 329.25M | 333.74M | 332.44M | 381.37M | 402.31M | - | 528.66M | 639.42M | 732.30M | 788.80M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 58.11M | 59.39M | 60.85M | 61.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | 10.68M | 38.56M | 39.21M | 38.19M | 41.76M | 57.27M | - | 89.18M | 183.50M | 213.39M | 156.12M |
| Investing Cash Flow | - | - | - | -16.93M | -39.50M | -36.89M | -42.18M | -50.53M | -36.41M | - | -32.78M | -649.12M | -124.93M | -70.33M |
| Financing Cash Flow | - | - | - | 2.24M | 7.14M | -7.72M | 25.01M | -3.78M | -2.25M | - | -26.44M | 454.09M | -80.95M | -67.42M |
| Capital Expenditure | -23.13M | -17.64M | -20.50M | -16.00M | -21.38M | -35.10M | -46.81M | -41.55M | -33.85M | - | -24.03M | -38.17M | -41.04M | -37.13M |
| Free Cash Flow | - | - | - | -5.32M | 17.18M | 4.11M | -8.62M | 207.00K | 23.41M | - | 65.15M | 145.34M | 172.34M | 118.98M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | 29.96M | -11.52M | 7.50M | 18.36M |
| Share Buybacks | 811.00K | 199.00K | 345.00K | 9.87M | 9.91M | 30.75M | 25.05M | 22.29M | 24.43M | 28.87M | 39.91M | 58.14M | 85.46M | 75.59M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 44.2% | 37.9% | 24.4% | 30.8% | 40.8% | 37.7% | 36.3% | 40.9% | 41.0% | - | 49.9% | 54.5% | 51.1% | 49.5% |
| Operating Margin % | 12.4% | 7.6% | -8.5% | -2.7% | 6.0% | -0.5% | -2.9% | -0.0% | 3.1% | - | 21.5% | 30.6% | 28.1% | 19.5% |
| Net Margin % | 8.9% | 5.2% | -5.1% | -1.1% | 3.8% | 1.5% | -1.9% | 15.2% | 0.4% | - | 18.3% | 21.3% | 21.8% | 13.6% |
| ROE % | 7.8% | 4.7% | -3.8% | -0.9% | 3.0% | 1.1% | -1.7% | 12.8% | 0.3% | - | 17.3% | 21.5% | 21.8% | 12.4% |
| ROCE % | - | 6.4% | -5.5% | -2.1% | 4.2% | -0.3% | -2.1% | -0.0% | 2.1% | - | 16.6% | 15.3% | 14.6% | 9.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.28% | 5.22M | $139.09M |
| 2 | Dimensional Fund Advisors LP | 5.42% | 2.31M | $61.36M |
| 3 | State Street Corporation | 3.86% | 1.64M | $43.71M |
| 4 | Vanguard Capital Management LLC | 3.48% | 1.48M | $39.45M |
| 5 | American Century Companies Inc | 2.77% | 1.18M | $31.32M |
| 6 | Marshall Wace LLP | 2.51% | 1.07M | $28.39M |
| 7 | Geode Capital Management, LLC | 2.28% | 969.84K | $25.82M |
| 8 | Fuller & Thaler Asset Management Inc. | 2.23% | 949.24K | $25.27M |
| 9 | Shaw D.E. & Co., Inc. | 2.09% | 887.05K | $23.61M |
| 10 | Vanguard Portfolio Management LLC | 1.90% | 809.57K | $21.55M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AMPH
Amphastar Pharmaceuticals (AMPH) Stock Looks About Right After A 42% Slide
Amphastar Pharmaceuticals has seen its share price move around in recent years, which puts a spotlight on whether the current US$25.87 level lines up with what its earnings really support. For anyone tracking the drug maker today, the key i…
1 Safe-and-Steady Stock to Research Further and 2 Facing Challenges
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to u…
3 Reasons to Avoid AMPH and 1 Stock to Buy Instead
Over the past six months, Amphastar Pharmaceuticals has been a great trade, beating the S&P 500 by 11.4%. Its stock price has climbed to $24.97, representing a healthy 29.8% increase. This was partly due to its solid quarterly results, and …
Amphastar Pharmaceuticals (NASDAQ:AMPH): Strongest Q2 Results from the Generic Pharmaceuticals Group
Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q2 generic pharmaceuticals earnings season.
Amphastar Pharmaceuticals (AMPH) Rebounds In Focus, Is It Slightly Overvalued?
Recent Price Moves Put Amphastar Pharmaceuticals in Focus Amphastar Pharmaceuticals (AMPH) has drawn fresh attention after recent share price swings, with the stock closing at $23.18 and showing mixed performance over the past week, month, …
AMPH — Frequently Asked Questions
What is the current share price of Amphastar Pharmaceuticals, Inc. (AMPH)?
As of 2026-10-23 16:27 PDT, Amphastar Pharmaceuticals, Inc. (AMPH) trades at $25.14 on NasdaqGS. Its 52-week range is $16.87 to $30.81.
What is the market capitalisation of AMPH?
Amphastar Pharmaceuticals, Inc. (AMPH) has a market capitalisation of $1.07B on NasdaqGS.
What is the P/E ratio of AMPH?
AMPH trades at a trailing price-to-earnings (P/E) ratio of 14.88. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.47.
What is the return on equity (ROE) of AMPH?
AMPH has a return on equity (ROE) of 10.30%. Its return on capital employed (ROCE) is 9.54%.
Is AMPH a good stock to buy?
This page provides a data-driven analysis of Amphastar Pharmaceuticals, Inc. (AMPH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.